Financing ·
Galera Therapeutics completed a $350 million Concurrent PIPE Financing by selling Series C Non-Voting Convertible…
GRTXDGalera Therapeutics, Inc.
Galera Therapeutics completed a $350 million Concurrent PIPE Financing by selling Series C Non-Voting Convertible Preferred Stock to qualified institutional buyers on July 31, 2026. This financing supports the previously announced merger with Obsidian Therapeutics under an Agreement and Plan of Merger dated April 14, 2026. The combined transaction is expected to close on August 3, 2026, subject to customary conditions. As part of the Pre-Closing Distribution, common stockholders will receive Contingent Value Rights (CVRs) for tilarganine and GC4711/GC4419 assets, with a record date of July 31, 2026, and distribution expected on August 6, 2026. Galera Therapeutics operates in the biotechnology industry, focusing on developing small molecule therapies for inflammatory diseases.